Last reviewed 2026-04-20 · How we verify

IBI308 200mg

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Anaemia
• White blood cell count decreased
• Neutrophil count decreased
• Platelet count decreased
• Alanine aminotransferase increased
• Nausea
• Aspartate aminotransferase increased
• Pyrexia
• Decreased appetite
• Asthenia
• Constipation
• Vomiting

Key clinical trials

• Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma (PHASE2)
• Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
• Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients (PHASE2)
• Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients (PHASE1)
• TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma (PHASE2)
• Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation (PHASE1)
• Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer (PHASE2)
• Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• IBI308 200mg CI brief — competitive landscape report
• IBI308 200mg updates RSS · CI watch RSS
• Innovent Biologics (Suzhou) Co. Ltd. portfolio CI